1. Penumbra will hold a Q2 2025 earnings call on July 29. 2. A press release for Q2 financial results will precede the call. 3. Penumbra specializes in thrombectomy technology for severe medical conditions. 4. Their products assist healthcare providers across over 100 countries. 5. Innovation in technology aims to enhance patient outcomes and quality of life.
While earnings announcements often influence stock prices, no significant news is presented.
The earnings call may clarify financial outlook but lacks major market-moving news.
Investor response may vary based on earnings results in the upcoming call.
Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day.
The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Penumbra, Inc.
Email: [email protected]
SOURCE Penumbra, Inc.